Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;102:994-999

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hingorani, A. D.
Right arrow Articles by Vallance, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hingorani, A. D.
Right arrow Articles by Vallance, P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITROGLYCERIN
*VERAPAMIL HYDROCHLORIDE
Related Collections
Right arrow Acute coronary syndromes
Right arrow Endothelium/vascular type/nitric oxide

(Circulation. 2000;102:994.)
© 2000 American Heart Association, Inc.


Clinical Investigation and Reports

Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in Humans

Aroon D. Hingorani, PhD, MRCP; Jenny Cross, BSc, MRCP; Rajesh K. Kharbanda, BSc, MRCP; Michael J. Mullen, MBBS, MRCP; Kiran Bhagat, PhD, MRCP; Mia Taylor, BSc; Ann E. Donald; Miriam Palacios, PhD; George E. Griffin, MD, FRCP; John E. Deanfield, MB, BChir, FRCP; Raymond J. MacAllister, MD, MRCP; Patrick Vallance, MD, FRCP

From the Centre for Clinical Pharmacology (A.D.H., J.C., R.K.K., K.B., R.J.M., P.V.) and Wolfson Institute for Biomedical Research (M.P.), University College London; Cardiothoracic Unit, Great Ormond Street Hospital for Children NHS Trust (M.J.M., M.T., A.E.D., J.E.D.); and Division of Infectious Diseases, School of Medicine, St George’s Hospital (G.E.G.), London, UK.

Correspondence to Dr A.D. Hingorani, Centre for Clinical Pharmacology, UCL, Rayne Institute, 5 University St, London WC1E 6JJ, UK. E-mail a.hingorani{at}ucl.ac.uk


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background—We tested the hypothesis that endothelial dysfunction underlies the association between an acute inflammatory episode and the transiently increased risk of a cardiovascular event by examining the effects of an experimental inflammatory stimulus on endothelium-dependent vasodilation.

Methods and ResultsSalmonella typhi vaccine was used to generate a systemic inflammatory response in healthy volunteers. In 12 subjects, dilatation of the brachial artery to flow and to sublingual nitroglycerin (NTG) was recorded (conduit vessel response), and in 6 subjects, venous occlusion plethysmography was used to measure forearm blood flow during intrabrachial infusion of the endothelium-dependent dilators acetylcholine (ACh) and bradykinin (BK) and the endothelium-independent dilators NTG and verapamil (resistance vessel response). Responses were assessed 16 hours before and 8 and 32 hours after vaccination. Vaccination resulted in elevations in white cell count and serum levels of interleukin-6 and interleukin-1 receptor antagonist. Eight hours after vaccination, resistance vessel responses to BK (P=0.0099) and ACh (P=0.0414) were markedly attenuated, and brachial artery flow-mediated dilatation was depressed. Resistance vessel responses to verapamil and NTG were unchanged, as was the conduit vessel response to NTG. Thirty-two hours after vaccination, resistance vessel responses to BK and ACh had returned to normal.

ConclusionsS typhi vaccine generates a mild inflammatory reaction associated with temporary but profound dysfunction of the arterial endothelium in both resistance and conduit vessels to both physical and pharmacological dilator stimuli. This finding might explain the association between infection and inflammation and the enhanced risk of an acute cardiovascular event.


Key Words: : endothelium • nitric oxide • coronary disease


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Epidemiological and observational studies have suggested an association between infection or inflammation and risk of cardiovascular disease.1 2 3 4 5 6 7 8 Two patterns of association have emerged: a link between chronic low-grade inflammation/infection and the slow process of atherogenesis,2 3 4 and an association between an acute systemic inflammatory response and a transiently increased risk of an acute cardiovascular event.5 6 7 8 The latter may underlie the increased cardiovascular morbidity and mortality seen after respiratory tract infection,9 severe illness requiring intensive care,6 or surgery.10

Previously, we have suggested that changes in endothelial activity may underpin the link between inflammation and the risk of an acute cardiovascular event.11 Loss of the normal vasodilator, antiplatelet, and antithrombotic properties of the vascular endothelium might tip the balance in favor of vasospasm, thrombosis, and inflammation and may contribute to the transition between "stable" and "unstable" atheroma. We have shown that local administration of certain proinflammatory cytokines impairs endothelium-dependent dilatation in human veins in vivo.12 In this study, we test directly the hypothesis that a mild systemic inflammatory response (generated by the administration of a vaccine) impairs endothelium-dependent dilatation in the arterial circulation.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Subjects
The protocol was approved by the University College London Hospitals Research Ethics Committee. All clinical studies were performed in a temperature-controlled laboratory (24°C to 26°C). Male and female subjects (age, 22 to 37 years) who stated that they were healthy, were not taking any medication, and had not received typhoid vaccination in the previous 6 months were included.

Generation of an Inflammatory Response
Salmonella typhi capsular polysaccharide vaccine 0.025 mg (Typhim Vi, Pasteur Merieux MSD) was injected into the gluteus muscle at 8 AM on the morning of day 2 of the study. In 6 subjects, the time course of the inflammatory response was documented by measurement of body temperature (by mercury thermometer) and pulse and blood pressure (by an automated device; Dinamap, Critikon Inc) immediately before and hourly for 8 hours after administration of the vaccine. At each of these time points, blood samples were taken for measurement of white cell and platelet counts and of cytokines. A further sample was also taken 32 hours after vaccination.

Measurement of Cytokines
Serum, obtained by centrifugation, was placed in aliquots and stored at -70°C for the measurement of interleukin-1ß (IL-1ß), interleukin-6 (IL-6), tumor necrosis factor-{alpha} (TNF-{alpha}), and interleukin-1 receptor antagonist (IL-1Ra) with a commercially available ELISA (Quantikine human IL-1ß, IL-6, TNF, and IL-1Ra immunoassays, R&D Systems).

Assessment of Forearm Blood Flow (Resistance Vessel Response)
Mercury-in-Silastic strain-gauge plethysmography was used to measure forearm blood flow (mL/100 mL forearm per minute) in both arms as described previously.13 14 For each study, the brachial artery of the nondominant arm was cannulated with a 27-gauge needle (Cooper’s Needle Works) inserted under local anesthesia (2 mL of 1% lignocaine). Drugs or normal saline (sodium chloride 0.9% wt/vol) were infused continuously at 0.5 mL/min. During recording periods, the hands were excluded from the circulation by inflation of wrist cuffs to 200 mm Hg. Forearm blood flow responses to intrabrachial infusions of 4 vasodilator drugs—bradykinin (BK), acetylcholine (ACh), nitroglycerin (NTG), and verapamil—were measured on 3 occasions at 4 PM on 3 consecutive days: 16 hours before and 8 and 32 hours after vaccine administration. The needle was removed at the end of each study period. Measurement of basal blood flow was made over a 15-minute period before drug infusion. The order of drug infusions was varied between studies, but because of its long duration of action,15 verapamil was always infused last. Saline was infused for 15 minutes between each drug infusion, and blood flow recordings were then made for a further 2 minutes to ensure that flow had returned to baseline values before the next drug infusion. The ratio of flow in the infused/noninfused (control) arm was calculated for each measurement period. Vasodilator responses were expressed as the percentage increase in the ratio of forearm blood flow (infused/noninfused arm) relative to the immediately preceding baseline flow, as described previously.13 15 In a further study of 5 control subjects, forearm blood flow responses to the 4 dilator drugs were compared 24 hours apart (at 4 PM) to determine whether there was a vaccine-independent change in dilator responsiveness over time.

Measurement of Brachial Artery Dilatation in Response to Flow and NTG (Conduit Vessel Response)
Brachial artery diameter in the nondominant arm was measured with high-resolution external vascular ultrasound (Acuson 128XP/10 with a 7.0-MHz linear-array transducer). The vessel was scanned in longitudinal section, and the center was identified when the clearest views of the anterior and posterior artery walls had been obtained. Images were magnified with a resolution box function and gated with the R wave of the ECG. End-diastolic images of the artery were acquired every 3 seconds with customized data-acquisition software (Information Integrity) and stored in digital format offline for later analysis.16 Arterial diameter over a 1- to 2-cm segment was determined for each image with a semiautomatic edge-detection algorithm. Blood flow velocity in the brachial artery was recorded continuously throughout the study with pulsed-wave Doppler. Brachial artery diameter and blood flow velocity were measured continuously for 1 minute at baseline, during 5 minutes of reduced blood flow (induced by inflation to 300 mm Hg of a pneumatic cuff placed at a site distal to the segment of artery being analyzed), and for a further 5 minutes during reactive hyperemia after cuff release. After return to baseline, vessel diameter was again measured continuously for 5 minutes after administration of 50 µg of sublingual NTG. Flow-mediated dilatation (FMD) was defined as the maximum percentage increase in vessel diameter during reactive hyperemia; NTG-mediated dilatation was defined as the maximum percentage increase in vessel diameter after sublingual NTG. In 12 subjects, measurements of FMD and NTG dilation were made serially 16 hours before and 8 hours after vaccination.

Drug Infusions
BK was obtained from Clinalfa AG; NTG, from David Bull Laboratories; ACh, from Sigma Chemical Co; and verapamil, from Knoll Ltd. BK, NTG, and ACh were prepared as stock solutions that were placed in aliquots and stored at -20°C until use. A fresh vial of verapamil was used for each study. Cumulative dose-response curves were constructed to BK (20, 40, and 80 pmol/min, each dose for 3 minutes), ACh (25, 50, and 100 nmol/min, each dose for 3 minutes), NTG (4, 8, and 16 nmol/min, each dose for 3 minutes), and verapamil (20, 40, and 80 nmol/min, each dose for 3 minutes).

Statistical Analysis
Results are expressed as mean±SEM unless otherwise stated. For conduit vessel responses, FMD and NTG dilatation were compared at each time point by a paired t test. For resistance vessel studies, dose–forearm blood flow response curves were constructed for all 4 drugs at each of the time points, and comparisons were made by repeated-measures ANOVA or 1- or 2-way ANOVA as appropriate. The paired t test or 1-sample t test was used for assessment of changes in inflammatory indexes and cytokine levels. P<0.05 was considered statistically significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Systemic Response to Vaccination
In the 8 hours after administration of capsular polysaccharide typhoid vaccine, total white cell count rose from 4.0±0.3x 109/L at baseline to 6.1±0.5x109/L at 8 hours (P<0.01) (see the TableDown). There was a progressive rise in the serum level of IL-6 from 2.1±0.4 pg/mL before vaccine to 5.8±3.2 pg/mL 8 hours after vaccine (P=0.07), and the level of IL-1Ra rose from a baseline value of 188.0±35.9 pg/mL to peak at 593.6±198.0 pg/mL 3 hours after vaccination, a 191% increase from baseline (P<0.05). There was no rise in the plasma level of IL-1 or TNF-{alpha} (data not shown) at the time points studied. Two subjects experienced local discomfort at the injection site, and 2 subjects reported generalized myalgia and headache. Temperature did not change significantly: 36.5±0.06°C at baseline and 36.7±0.05°C at 8 hours (P=NS).


View this table:
[in this window]
[in a new window]
 
Table 1. Inflammatory Response to Vaccination

Resistance Vessel Responses
Vaccine Study
Vaccination had no effect on blood pressure or resting heart rate, nor did it alter baseline forearm blood flow measured by venous occlusion plethysmography. Mean baseline blood flow was 4.72±0.64 mL/100 mL forearm per minute before vaccination, 4.70±0.70 mL/100 mL forearm per minute 8 hours after vaccination, and 4.04±0.54 mL/100 mL forearm per minute 32 hours after vaccination (P=NS). Before vaccination, all subjects showed a dose-dependent increase in forearm blood flow to the endothelium-dependent vasodilators BK and ACh (Figure 1aDown and 1bDown) and to the endothelium-independent vasodilators NTG and verapamil (Figure 1cDown and 1dDown). When the dilator response was reassessed 8 hours after vaccination, there was a selective and marked blunting of the response to BK (P<0.0099 by repeated-measures ANOVA; Figure 1aDown) and an impaired response to ACh (P=0.0414 by repeated measures ANOVA; Figure 1bDown). Impairment of the ACh response was most marked at the highest dose of ACh used (P=0.0004 by repeated-measures ANOVA of the 100-nmol/min data). There was no significant change in the response to NTG (Figure 1cDown) or to verapamil (Figure 1dDown). Thirty-two hours after vaccination, the response to BK had returned to normal (FigureDown 1a), and the responses to NTG (Figure 1cDown) and verapamil (Figure 1dDown) were again unchanged. The endothelium appeared more sensitive to the effects of ACh at this time point, at least at the 25- and 50-nmol/min doses, although the response to the maximum dose of ACh was similar to the level observed before vaccination.



View larger version (13K):
[in this window]
[in a new window]
 
Figure 1. Forearm blood flow responses to incremental doses of (a) BK, (b) ACh, (c) NTG (GTN), and (d) verapamil in vaccinated subjects (n=6; P by repeated-measures ANOVA). *P=0.0004 by repeated-measures ANOVA of response to 100 nmol/min ACh (see text).

Control Study
When forearm blood flow studies were performed twice (24 hours apart) in 5 nonvaccinated subjects, the responses to BK (Figure 2aDown), ACh (Figure 2bDown), and NTG (Figure 2cDown) were unchanged over the 24-hour period. There was a significant reduction in the response to verapamil on day 2 (P=0.0093 by 2-way ANOVA; Figure 2dDown), although individual dilator responses to this drug proved to be more variable than for the other agents.



View larger version (12K):
[in this window]
[in a new window]
 
Figure 2. Forearm blood flow responses to incremental doses of (a) BK, (b) ACh, (c) NTG (GTN), and (d) verapamil in nonvaccinated subjects (n=5; P by 2-way ANOVA).

Conduit Artery Responses
Baseline brachial artery diameter and blood flow velocity–time index did not change during the study. However, compared with prevaccination values, there was a significant impairment in FMD by 8 hours after vaccination (mean FMD, 6.5±0.5 before versus 5.0±0.5 at 8 hours after vaccination; P<0.05; Figure 3Down). In contrast, there was no difference in the NTG response at these 2 time points (9.5±0.7 versus 9.5±0.9, P=NS; Figure 3Down).



View larger version (19K):
[in this window]
[in a new window]
 
Figure 3. Maximal dilatation of the brachial artery in response to (a) flow and (b) sublingual NTG (GTN; 50 µg) in 12 subjects measured at baseline and 8 hours after vaccination. Individual responses are shown in a and b; group mean±SEM responses are shown in insets (P by paired t-test).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Intramuscular injection of capsular polysaccharide typhoid vaccine produced a mild systemic inflammatory response in healthy volunteers that was associated with profound, but temporary, suppression of endothelium-dependent relaxation in the forearm circulation. These findings demonstrate that even a relatively mild systemic inflammatory response is associated with significant alteration in endothelial function of a type commonly thought to be associated with increased cardiovascular risk.13 17 18 19

Inflammatory Response to Vaccination
To initiate a systemic inflammatory response, we gave an intramuscular injection of the capsular polysaccharide typhoid vaccine Typhim Vi.20 In the 8 hours after vaccination, there was a mild leukocytosis but no change in blood pressure or heart rate (see TableUp). Over this time, the plasma concentration of the proinflammatory cytokine IL-6 increased, but there was no change in the concentration of either IL-1ß or TNF-{alpha}. These results are similar to those reported previously with the whole-cell typhoid vaccine21 and suggest that IL-6 may be an important cytokine contributing to the response seen after this type of vaccination.

Although the serum concentrations of IL-1ß and TNF-{alpha} did not change, the concentration of the endogenous IL-1Ra was elevated at 3 hours after vaccination. IL-1Ra is usually synthesized in response to IL-1ß generation,22 and the results are compatible with the suggestion23 that significant local cellular or tissue generation of cytokines can occur without an increase in circulating concentrations. Therefore, we cannot exclude the possibility that IL-1ß and TNF-{alpha} were synthesized after vaccination or indeed that other cytokines that we did not measure contributed to the responses seen. However, in relation to cardiovascular risk, the elevation of IL-6 is of particular interest because IL-6 is presumed to be an important, if not the principal, stimulus to the synthesis of C-reactive protein,24 and elevated C-reactive protein seems to be predictive of risk of cardiovascular events.2 4

The increase in IL-6 and IL-Ra levels observed in vaccinated subjects cannot be explained by diurnal changes in these cytokines. IL-1Ra shows no diurnal variation,25 and although the levels of IL-6 do vary over a 24-hour period in subjects with inflammatory disorders,26 the levels are highest in the morning and not in the afternoon, as we observed in the vaccinated subjects.

Endothelium-Dependent Responses After Vaccination
Resistance Vessel Studies
Forearm arteriolar vasodilation was assessed in healthy volunteers before and at various times after vaccination, with each study performed at the same time of day. Dilator dose-response curves were constructed to local intra-arterial infusion of agents whose dilator action is dependent on a functional vascular endothelium (BK and ACh) and to agents whose action is to relax directly vascular smooth muscle (NTG and verapamil). BK and ACh have been used widely to probe the ability of the endothelium to generate vasodilator factors; both agents work in part through stimulation of nitric oxide generation in this vascular bed.27 Decreased efficacy or potency of BK or ACh in the forearm arterial bed has been detected in patients with a wide variety of cardiovascular disease states, including hypertension,13 19 diabetes,15 and hypercholesterolemia,18 and has been taken as an indication of endothelial dysfunction. In the present study, responses to BK 8 hours after vaccination were suppressed by {approx}65%. The response to ACh was also diminished, particularly at the highest dose used. This finding of selective impairment in ACh responses at doses equivalent to >=100 nmol/min has also been noted in patients with hypertension.28 Suppression of endothelium-dependent dilation was not seen in nonvaccinated individuals studied on consecutive days, and the magnitude of change seen after vaccination was as at least as great as the changes reported in the presence of classical cardiovascular risk factors.17 18 19 The effect of vaccination was specific for agonists working through the endothelium, because responses to the nitric oxide donor drug NTG and the calcium channel blocker verapamil were unaltered. In the case of BK, the defect in endothelium-dependent relaxation had returned to normal by 32 hours. At this time point, the endothelium appeared more sensitive to the lower doses of ACh, although the response to the maximal dose of ACh was unchanged. The reason for this difference between the 2 agonists with respect to the recovery of endothelium dependent dilator function is not clear. It may reflect differences in the recovery of receptor or postreceptor signaling mechanisms or might be the result of greater interindividual variability in the response to ACh, which has been documented previously.29 Indeed, the data for ACh were found to be particularly variable, and the results with this agonist should be interpreted with caution.

In nonvaccinated subjects, the responses to BK, ACh, and NTG were unchanged over 24 hours. The dilator response to verapamil was depressed on day 2 of the study in these subjects. The more marked intersubject variability in the response to verapamil might account for this observation, but in any case, it was clear that vaccination did not suppress the dilator response to this agent. In summary, for resistance vessels, vaccination caused a clear suppression of BK dilatation without altering the response to NTG. The response to ACh was also altered, but these results should be interpreted in light of a greater individual variability in ACh response. Verapamil response was unchanged by vaccination, but again the responses to this agent are more variable.

Conduit Vessel Studies
After vaccination, the attenuation in endothelium-dependent vasodilatation in resistance vessels in response to pharmacological stimuli was mirrored by an attenuation in the dilator response of a conduit vessel to a physical stimulus (flow). This attenuation in response occurred in the absence of any change in the response to a submaximal dilator dose of sublingual NTG. FMD of a peripheral artery appears to be dependent on the release of endothelium-derived nitric oxide,30 and a reduction in brachial artery FMD has been observed in individuals with risk factors for atherosclerosis,31 including hypercholesterolemia,32 and in those with established coronary artery disease.33 Therefore, an attenuation in brachial artery FMD has also come to be regarded as indicating the presence of endothelial dysfunction.

The results demonstrate that vaccination with capsular polysaccharide typhoid vaccine temporarily but profoundly impairs the ability of the arterial endothelium to produce endogenous vasodilators in response to agonist and physical stimuli. The endothelium is an important transducer of physical and chemical signals from the lumen of the vessel, and experiments in animals and in vitro suggest that the changes reported here could alter vascular behavior to contribute to disruption of tissue oxygenation, increased platelet and white cell adhesion to the vessel wall,34 and a predisposition to vasospasm. Relaxation to BK was affected most, and this may be particularly important because local generation of BK plays a role in vascular homeostasis.35

Mechanisms and Clinical Implications
The mechanism(s) by which inflammation may impair endothelium-dependent relaxation are not fully understood. One possibility is that certain cytokines induce de novo expression of the inducible isoform of nitric oxide synthase (iNOS) in the vessel wall (an isoform implicated in the high-output nitric oxide production seen in inflammation and sepsis), and this high output of NO, coupled with the generation of superoxide, causes endothelial damage.36 This is unlikely to be the explanation of our findings because expression of iNOS would be expected to cause vasodilatation and neither blood pressure nor resting forearm flow changed significantly after vaccination. Furthermore, although we did not test basal nitric oxide–mediated dilatation in this study, it has been shown previously that the conversion of 15N-arginine to 15NO3- (a breakdown product of NO) does not increase after administration of whole-cell typhoid vaccine to healthy volunteers.37

An alternative possibility is that the cytokines caused a decrease in the expression of the constitutive endothelial NOS (eNOS). However, this is unlikely to be the sole mechanism, because in our previous studies in human veins we found no decrease in mRNA encoding eNOS after cytokine administration38 and because, in the earlier study, the defect was not confined to nitric oxide–mediated dilatation but also included prostanoid-mediated dilatation.12 Further studies are required to elucidate the mechanisms underlying the effects seen and the extent to which the endothelium loses its capacity to respond to other chemical and physical signals after inflammation.

Systemic inflammation far more severe and long-lasting than the insult produced by vaccination occurs in a wide variety of infective disorders and after iatrogenic procedures such as abdominal surgery. There is growing evidence that acute systemic inflammation is associated with an increase in the risk of cardiovascular events that may persist for days or weeks.8 9 There is also evidence that unstable angina is associated with inflammation,5 which might precede the onset of the syndrome. The present study demonstrates that even a mild inflammatory reaction disturbs endothelial regulation of vascular tone in the arterial circulation. It is important to determine whether the changes reported here are also seen after clinical inflammatory states and whether they might be a target for therapy.


View this table:
[in this window]
[in a new window]
 
Table 1A. Continued


*    Acknowledgments
 
This study was supported by the British Heart Foundation through Research Fellowships to Drs Bhagat and Kharbanda and the British Heart Foundation (Gerry Turner) Intermediate Fellowship to Dr Hingorani. Dr Cross is supported by UCL Hospitals Trustees. We thank Dr Derek Macallan, Division of Infectious Diseases, St George’s Hospital Medical School, for a critical reading of the manuscript.

Received October 26, 1999; revision received March 22, 2000; accepted March 27, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Maseri A. Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon. N Engl J Med. 1997;336:1014–1016.[Free Full Text]

2. Ridker PM, Cushman P, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979.[Abstract/Free Full Text]

3. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and the risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88–92.[Medline] [Order article via Infotrieve]

4. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425–428.[Abstract/Free Full Text]

5. Liuzzo G, Biassuci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417–424.[Abstract/Free Full Text]

6. Quartin AA, Schein RMH, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival. JAMA. 1997;277:1058–1063.[Abstract/Free Full Text]

7. Valtonen V, Kuikka A, Syrjanen J. Thrombo-embolic complications in bacteraemic infections. Eur Heart J. 1993;14(suppl K):20–23.

8. Tillett HE, Smith JW, Gooch CD. Excess deaths attributed to influenza in England and Wales: age at death and certified cause. Int J Epidemiol. 1983;12:344–352.[Abstract/Free Full Text]

9. Meier CR, Jick SS, Derby LE, et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet. 1998;351:1467–1471.[Medline] [Order article via Infotrieve]

10. Mamod N, Cobbe S, Pollock JG. Infarcts after surgery. BMJ. 1995;310:1215–1216.[Free Full Text]

11. Vallance P, Collier J, Bhagat K. Infection, inflammation and infarction: does acute endothelial dysfunction provide the link? Lancet. 1997;349:1391–1392.[Medline] [Order article via Infotrieve]

12. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation. 1997;96:3042–3047.[Abstract/Free Full Text]

13. Calver A, Collier J, Moncada S, et al. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 1992;10:1025–1031.[Medline] [Order article via Infotrieve]

14. Benjamin N, Calver A, Collier J, et al. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension. 1995;25:918–923.[Abstract/Free Full Text]

15. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest. 1992;90:2548–2554.

16. Mullen MJ, Thorne SA, Deanfield JE, et al. Non-invasive assessment of endothelial function. Heart. 1997;77:297–298.[Free Full Text]

17. Gerhard M, Roddy MA, Creager SJ, et al. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension. 1996;27:849–853.[Abstract/Free Full Text]

18. Chowienczyk PJ, Watts GF, Cockcroft JR, et al. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet. 1992;340:1430–1432.[Medline] [Order article via Infotrieve]

19. Panza JA, Quyyumi AA, Brush JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22–27.[Abstract]

20. Plotkin SA, Bouveretlecam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Intern Med. 1995;155:2293–2299.[Abstract/Free Full Text]

21. Cooper AL, Horan MA, Little RA, et al. Metabolic and febrile responses to typhoid vaccine in humans: effect of beta adrenergic blockade. J Appl Physiol. 1992;72:2322–2328.[Abstract/Free Full Text]

22. Granowitz EV, Santos AA, Poutsiaka DD, et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet. 1991;338:1423–1445.[Medline] [Order article via Infotrieve]

23. Dinarello CA. Blocking interleukin-1 in sepsis. J Endotoxin Res. 1995;2:157–162.

24. Gauldie J, Richards C, Northeman W, et al. IFNB2/BSF2/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute phase gene regulation in hepatocytes. Ann N Y Acad Sci. 1989;557:46–59.[Medline] [Order article via Infotrieve]

25. Chikanza IC, Roux-Lombard P, Dayer JM, et al. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis: pathogenetic implications. Arthritis Rheum. 1995;38:642–648.[Medline] [Order article via Infotrieve]

26. Arvidson AG, Gudbjornsson B, Elfman L, et al. Ann Rheum Dis. 1994; 53:521–524.

27. Vallance P. Vascular endothelium, its physiology and pathophysiology. In: Wetherall DJ, Ledingham JGG, Warrell DA, eds. Oxford Textbook of Medicine. Oxford, UK: Oxford University Press; 1995:2295–2300.

28. Taddei S, Viridis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with hypertension. Circulation. 1995;91:1981–1987.[Abstract/Free Full Text]

29. Chowienczyk P, Cockcroft JR, Ritter JM. Blood flow responses to intra-arterial acetylcholine in man: effects of basal flow and conduit vessel length. Clin Sci. 1994;87:45–51.[Medline] [Order article via Infotrieve]

30. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314–1319.[Abstract/Free Full Text]

31. Celermajer DS, Sorensen KE, Bull C, et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24:1468–1474.[Abstract]

32. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–1115.[Medline] [Order article via Infotrieve]

33. Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol. 1996;78:1210–1214.[Medline] [Order article via Infotrieve]

34. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057–1058.[Medline] [Order article via Infotrieve]

35. Groves P, Kurz S, Just H, et al. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995;92:3424–3430.[Abstract/Free Full Text]

36. Beckmann JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol Cell Physiol. 1996;271:C1424–C1437.[Abstract/Free Full Text]

37. Macallan DC, Smith LM, Ferber J, et al. Measurement of NO synthesis in humans by L-[N-15(2)] arginine: application to the response to vaccination. Am J Physiol Regul Integrative Comp Physiol. 1997;41:R1888–R1896.

38. Bhagat K, Hingorani AD, Palacios M, et al. Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS. Cardiovasc Res. 1999;41:754–764.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Eur Heart JHome page
L. Lind, L. Wallentin, T. Kempf, H. Tapken, A. Quint, B. Lindahl, S. Olofsson, P. Venge, A. Larsson, J. Hulthe, et al.
Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study
Eur. Heart J., October 1, 2009; 30(19): 2346 - 2353.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
Y-J Kim, J-I Shin, K-W Park, H-Y Lee, H-J Kang, B-K Koo, B-J Park, D-W Sohn, B-H Oh, Y-B Park, et al.
The effect of granulocyte-colony stimulating factor on endothelial function in patients with myocardial infarction
Heart, August 15, 2009; 95(16): 1320 - 1325.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. J. Peterson, D. H. Kim, M. Li, V. Positano, L. Vanella, L. F. Rodella, F. Piccolomini, N. Puri, A. Gastaldelli, C. Kusmic, et al.
The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice
J. Lipid Res., July 1, 2009; 50(7): 1293 - 1304.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A Yilmaz, H Mahrholdt, A Athanasiadis, H Vogelsberg, G Meinhardt, M Voehringer, E-M Kispert, C Deluigi, H Baccouche, E Spodarev, et al.
Coronary vasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis
Heart, November 1, 2008; 94(11): 1456 - 1463.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
L. Edvinsson and S. E. Andersson
Commentary on Viewpoint: The human cutaneous circulation as a model of generalized microvascular function
J Appl Physiol, July 1, 2008; 105(1): 381 - 381.
[Full Text] [PDF]


Home page
ThoraxHome page
N L Mills, J J Miller, A Anand, S D Robinson, G A Frazer, D Anderson, L Breen, I B Wilkinson, C M McEniery, K Donaldson, et al.
Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk
Thorax, April 1, 2008; 63(4): 306 - 311.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
P. C. Colombo, D. Onat, and H. N. Sabbah
Acute heart failure as "acute endothelitis" -- Interaction of fluid overload and endothelial dysfunction
Eur J Heart Fail, February 1, 2008; 10(2): 170 - 175.
[Full Text] [PDF]


Home page
Ann Rheum DisHome page
H Pieringer, U Stuby, S Hargassner, and G Biesenbach
Treatment with corticosteroids reduces arterial stiffness in patients with polymyalgia rheumatica as measured with pulse wave analysis
Ann Rheum Dis, February 1, 2008; 67(2): 279 - 279.
[Full Text] [PDF]


Home page
HypertensionHome page
M. Briet, C. Collin, S. Laurent, A. Tan, M. Azizi, M. Agharazii, X. Jeunemaitre, F. Alhenc-Gelas, and P. Boutouyrie
Endothelial Function and Chronic Exposure to Air Pollution in Normal Male Subjects
Hypertension, November 1, 2007; 50(5): 970 - 976.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
M. M. Zanone, E. Favaro, E. Ferioli, G. C. Huang, N. J. Klein, P. C. Perin, M. Peakman, P. G. Conaldi, and G. Camussi
Human pancreatic islet endothelial cells express coxsackievirus and adenovirus receptor and are activated by coxsackie B virus infection
FASEB J, October 1, 2007; 21(12): 3308 - 3317.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. Vlachopoulos, K. Aznaouridis, A. Dagre, C. Vasiliadou, C. Masoura, E. Stefanadi, J. Skoumas, C. Pitsavos, and C. Stefanadis
Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects
Eur. Heart J., September 1, 2007; 28(17): 2102 - 2109.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. Smeeth, J. P. Casas, and A. D. Hingorani
The role of infection in cardiovascular disease: more support but many questions remain
Eur. Heart J., May 2, 2007; 28(10): 1178 - 1179.
[Full Text] [PDF]


Home page
Diabetes CareHome page
J. A. Beckman, A. B. Goldfine, A. Dunaif, M. Gerhard-Herman, and M. A. Creager
Endothelial Function Varies According to Insulin Resistance Disease Type
Diabetes Care, May 1, 2007; 30(5): 1226 - 1232.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. S. Tonetti, F. D'Aiuto, L. Nibali, A. Donald, C. Storry, M. Parkar, J. Suvan, A. D. Hingorani, P. Vallance, and J. Deanfield
Treatment of Periodontitis and Endothelial Function
N. Engl. J. Med., March 1, 2007; 356(9): 911 - 920.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. M. Luther, J. V. Gainer, L. J. Murphey, C. Yu, D. E. Vaughan, J. D. Morrow, and N. J. Brown
Angiotensin II Induces Interleukin-6 in Humans Through a Mineralocorticoid Receptor-Dependent Mechanism
Hypertension, December 1, 2006; 48(6): 1050 - 1057.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. A. Marsden
Inflammation and Coagulation in the Cardiovascular System: The Contribution of Influenza
Circ. Res., November 24, 2006; 99(11): 1152 - 1153.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. E. Donald, M. Charakida, T. J. Cole, P. Friberg, P. J. Chowienczyk, S. C. Millasseau, J. E. Deanfield, and J. P. Halcox
Non-Invasive Assessment of Endothelial Function: Which Technique?
J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1846 - 1850.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. M. Maki-Petaja, F. C. Hall, A. D. Booth, S. M.L. Wallace, Yasmin, P. W.P. Bearcroft, S. Harish, A. Furlong, C. M. McEniery, J. Brown, et al.
Rheumatoid Arthritis Is Associated With Increased Aortic Pulse-Wave Velocity, Which Is Reduced by Anti-Tumor Necrosis Factor-{alpha} Therapy
Circulation, September 12, 2006; 114(11): 1185 - 1192.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Heitzer, V. Rudolph, E. Schwedhelm, M. Karstens, K. Sydow, M. Ortak, P. Tschentscher, T. Meinertz, R. Boger, and S. Baldus
Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery Disease: Evidence for Antioxidant and Antiinflammatory Effects
Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1648 - 1652.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Hermann and F. Ruschitzka
Novel anti-inflammatory drugs in hypertension
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 859 - 864.
[Full Text] [PDF]


Home page
DiabetesHome page
A. Natali, E. Toschi, S. Baldeweg, D. Ciociaro, S. Favilla, L. Sacca, and E. Ferrannini
Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes.
Diabetes, April 1, 2006; 55(4): 1133 - 1140.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
C. Zoccali
Endothelial Dysfunction and the Kidney: Emerging Risk Factors for Renal Insufficiency and Cardiovascular Outcomes in Essential Hypertension.
J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S61 - S63.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. H. Shen, L. Zhang, Y. Gan, X. Wang, J. Wang, S. A. LeMaire, J. S. Coselli, and X. L. Wang
Up-regulation of PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome Ten) Mediates p38 MAPK Stress Signal-induced Inhibition of Insulin Signaling: A CROSS-TALK BETWEEN STRESS SIGNALING AND INSULIN SIGNALING IN RESISTIN-TREATED HUMAN ENDOTHELIAL CELLS
J. Biol. Chem., March 24, 2006; 281(12): 7727 - 7736.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
C. Vlachopoulos, F. Kosmopoulou, N. Alexopoulos, N. Ioakeimidis, G. Siasos, and C. Stefanadis
Acute mental stress has a prolonged unfavorable effect on arterial stiffness and wave reflections.
Psychosom Med, March 1, 2006; 68(2): 231 - 237.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
H K Chang, S K Kim, S S Lee, and M Y Rhee
Arterial stiffness in Behcet's disease: increased regional pulse wave velocity values
Ann Rheum Dis, March 1, 2006; 65(3): 415 - 416.
[Full Text] [PDF]


Home page
CirculationHome page
N. L. Mills, H. Tornqvist, S. D. Robinson, M. Gonzalez, K. Darnley, W. MacNee, N. A. Boon, K. Donaldson, A. Blomberg, T. Sandstrom, et al.
Diesel Exhaust Inhalation Causes Vascular Dysfunction and Impaired Endogenous Fibrinolysis
Circulation, December 20, 2005; 112(25): 3930 - 3936.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
F. C. Hall and N. Dalbeth
Disease modification and cardiovascular risk reduction: two sides of the same coin?
Rheumatology, December 1, 2005; 44(12): 1473 - 1482.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Mahmud and J. Feely
Arterial Stiffness Is Related to Systemic Inflammation in Essential Hypertension
Hypertension, November 1, 2005; 46(5): 1118 - 1122.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Vlachopoulos, I. Dima, K. Aznaouridis, C. Vasiliadou, N. Ioakeimidis, C. Aggeli, M. Toutouza, and C. Stefanadis
Acute Systemic Inflammation Increases Arterial Stiffness and Decreases Wave Reflections in Healthy Individuals
Circulation, October 4, 2005; 112(14): 2193 - 2200.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
R. H Boger
Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials
Vascular Medicine, July 1, 2005; 10(1_suppl): S19 - S25.
[Abstract] [PDF]


Home page
Rheumatology (Oxford)Home page
C. D. Buckley, G. E. Rainger, G. B. Nash, and K. Raza
Endothelial cells, fibroblasts and vasculitis
Rheumatology, July 1, 2005; 44(7): 860 - 863.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
R. H Boger
Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials
Vascular Medicine, May 1, 2005; 10(2_suppl): S19 - S25.
[Abstract] [PDF]


Home page
CirculationHome page
K. B. Vallbracht, P. L. Schwimmbeck, U. Kuhl, U. Rauch, B. Seeberg, and H.-P. Schultheiss
Differential Aspects of Endothelial Function of the Coronary Microcirculation Considering Myocardial Virus Persistence, Endothelial Activation, and Myocardial Leukocyte Infiltrates
Circulation, April 12, 2005; 111(14): 1784 - 1791.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Charakida, A. E. Donald, M. Terese, S. Leary, J. P. Halcox, A. Ness, G. D. Smith, J. Golding, P. Friberg, N. J. Klein, et al.
Endothelial Dysfunction in Childhood Infection
Circulation, April 5, 2005; 111(13): 1660 - 1665.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. R. Clapp, G. M. Hirschfield, C. Storry, J. R. Gallimore, R. P. Stidwill, M. Singer, J. E. Deanfield, R. J. MacAllister, M. B. Pepys, P. Vallance, et al.
Inflammation and Endothelial Function: Direct Vascular Effects of Human C-Reactive Protein on Nitric Oxide Bioavailability
Circulation, March 29, 2005; 111(12): 1530 - 1536.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. Vila and M. Salaices
Cytokines and vascular reactivity in resistance arteries
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1016 - H1021.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. K. Kharbanda, S. Wallace, B. Walton, A. Donald, J. M. Cross, and J. Deanfield
Systemic Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Inflammation and Improves Vascular Function in Hypercholesterolemia
Circulation, February 15, 2005; 111(6): 804 - 807.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. D. Katz, K. Hryniewicz, I. Hriljac, K. Balidemaj, C. Dimayuga, A. Hudaihed, and A. Yasskiy
Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart Failure
Circulation, January 25, 2005; 111(3): 310 - 314.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
L. Smeeth, S. L. Thomas, A. J. Hall, R. Hubbard, P. Farrington, and P. Vallance
Risk of Myocardial Infarction and Stroke after Acute Infection or Vaccination
N. Engl. J. Med., December 16, 2004; 351(25): 2611 - 2618.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. A. Vita, J. F. Keaney Jr, M. G. Larson, M. J. Keyes, J. M. Massaro, I. Lipinska, B. T. Lehman, S. Fan, E. Osypiuk, P. W.F. Wilson, et al.
Brachial Artery Vasodilator Function and Systemic Inflammation in the Framingham Offspring Study
Circulation, December 7, 2004; 110(23): 3604 - 3609.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Pleiner, G. Schaller, F. Mittermayer, S. Zorn, C. Marsik, S. Polterauer, S. Kapiotis, and M. Wolzt
Simvastatin Prevents Vascular Hyporeactivity During Inflammation
Circulation, November 23, 2004; 110(21): 3349 - 3354.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. B. Vallbracht, P. L. Schwimmbeck, U. Kuhl, B. Seeberg, and H.-P. Schultheiss
Endothelium-Dependent Flow-Mediated Vasodilation of Systemic Arteries Is Impaired in Patients With Myocardial Virus Persistence
Circulation, November 2, 2004; 110(18): 2938 - 2945.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Bennermo, C. Held, S. Stemme, C.-G. Ericsson, A. Silveira, F. Green, and P. Tornvall
Genetic Predisposition of the Interleukin-6 Response to Inflammation: Implications for a Variety of Major Diseases?
Clin. Chem., November 1, 2004; 50(11): 2136 - 2140.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Fichtlscherer, S. Breuer, and A. M. Zeiher
Prognostic Value of Systemic Endothelial Dysfunction in Patients With Acute Coronary Syndromes: Further Evidence for the Existence of the "Vulnerable" Patient
Circulation, October 5, 2004; 110(14): 1926 - 1932.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. R. Clapp, A. D. Hingorani, R. K. Kharbanda, V. Mohamed-Ali, J. W. Stephens, P. Vallance, and R. J. MacAllister
Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress
Cardiovasc Res, October 1, 2004; 64(1): 172 - 178.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
R. H. Boger
Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Explains the "L-Arginine Paradox" and Acts as a Novel Cardiovascular Risk Factor
J. Nutr., October 1, 2004; 134(10): 2842S - 2847S.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. P. Didion, D. A. Kinzenbaw, P. E. Fegan, L. A. Didion, and F. M. Faraci
Overexpression of CuZn-SOD Prevents Lipopolysaccharide-Induced Endothelial Dysfunction
Stroke, August 1, 2004; 35(8): 1963 - 1967.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. El-Magadmi, H. Bodill, Y. Ahmad, P. N. Durrington, M. Mackness, M. Walker, R. M. Bernstein, and I. N. Bruce
Systemic Lupus Erythematosus: An Independent Risk Factor for Endothelial Dysfunction in Women
Circulation, July 27, 2004; 110(4): 399 - 404.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
H Teragawa, Y Fukuda, K Matsuda, K Ueda, Y Higashi, T Oshima, M Yoshizumi, and K Chayama
Relation between C reactive protein concentrations and coronary microvascular endothelial function
Heart, July 1, 2004; 90(7): 750 - 754.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
U. Landmesser, B. Hornig, and H. Drexler
Endothelial Function: A Critical Determinant in Atherosclerosis?
Circulation, June 1, 2004; 109(21_suppl_1): II-27 - II-33.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Yasmin, C. M. McEniery, S. Wallace, I. S. Mackenzie, J. R. Cockcroft, and I. B. Wilkinson
C-Reactive Protein Is Associated With Arterial Stiffness in Apparently Healthy Individuals
Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 969 - 974.
[Abstract] [Full Text]


Home page
JAMAHome page
J. B. Meigs, F. B. Hu, N. Rifai, and J. E. Manson
Biomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus
JAMA, April 28, 2004; 291(16): 1978 - 1986.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A.D. Booth, D.R.W. Jayne, R.K. Kharbanda, C.M. McEniery, I.S. Mackenzie, J. Brown, and I.B. Wilkinson
Infliximab Improves Endothelial Dysfunction in Systemic Vasculitis: A Model of Vascular Inflammation
Circulation, April 13, 2004; 109(14): 1718 - 1723.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
P. C. Tong, K.-F. Lee, W.-Y. So, M. H. Ng, W.-B. Chan, M. K. Lo, N. N. Chan, and J. C. Chan
White Blood Cell Count Is Associated With Macro- and Microvascular Complications in Chinese Patients With Type 2 Diabetes
Diabetes Care, January 1, 2004; 27(1): 216 - 222.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
G Vaudo, S Marchesi, R Gerli, R Allegrucci, A Giordano, D Siepi, M Pirro, Y Shoenfeld, G Schillaci, and E Mannarino
Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity
Ann Rheum Dis, January 1, 2004; 63(1): 31 - 35.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. V. Anderson
Angiotensin-converting enzyme inhibitors: ischemia is not the correct measure of benefit
J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2060 - 2062.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
L. M. Title, K. Giddens, M. M. McInerney, M. J. McQueen, and B. A. Nassar
Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease
J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1747 - 1753.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
G.M. Hirschfield and M.B. Pepys
C-reactive protein and cardiovascular disease: new insights from an old molecule
QJM, November 1, 2003; 96(11): 793 - 807.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. E. Widlansky, N. Gokce, J. F. Keaney Jr, and J. A. Vita
The clinical implications of endothelial dysfunction
J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1149 - 1160.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. M. R. Gill, M. J. Caslake, C. McAllister, F. Tsofliou, W. R. Ferrell, C. J. Packard, and D. Malkova
Effects of Short-Term Detraining on Postprandial Metabolism, Endothelial Function, and Inflammation in Endurance-Trained Men: Dissociation between Changes in Triglyceride Metabolism and Endothelial Function
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4328 - 4335.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Grahame-Clarke, N. N. Chan, D. Andrew, G. L. Ridgway, D. J. Betteridge, V. Emery, H. M. Colhoun, and P. Vallance
Human Cytomegalovirus Seropositivity Is Associated With Impaired Vascular Function
Circulation, August 12, 2003; 108(6): 678 - 683.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Amar, N. Gokce, S. Morgan, M. Loukideli, T. E. Van Dyke, and J. A. Vita
Periodontal Disease Is Associated With Brachial Artery Endothelial Dysfunction and Systemic Inflammation
Arterioscler Thromb Vasc Biol, July 1, 2003; 23(7): 1245 - 1249.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. A. Vogel
Heads and Hearts: The Endothelial Connection
Circulation, June 10, 2003; 107(22): 2766 - 2768.
[Full Text] [PDF]


Home page
Diabetes CareHome page
A. Sciacqua, M. Candigliota, R. Ceravolo, A. Scozzafava, F. Sinopoli, A. Corsonello, G. Sesti, and F. Perticone
Weight Loss in Combination With Physical Activity Improves Endothelial Dysfunction in Human Obesity
Diabetes Care, June 1, 2003; 26(6): 1673 - 1678.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
R Klocke, J R Cockcroft, G J Taylor, I R Hall, and D R Blake
Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis
Ann Rheum Dis, May 1, 2003; 62(5): 414 - 418.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Weis and J. P. Cooke
Cardiac Allograft Vasculopathy and Dysregulation of the NO Synthase Pathway
Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 567 - 575.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Chia, M. Qadan, R. Newton, C. A. Ludlam, K. A.A. Fox, and D. E. Newby
Intra-Arterial Tumor Necrosis Factor-{alpha} Impairs Endothelium-Dependent Vasodilatation and Stimulates Local Tissue Plasminogen Activator Release in Humans
Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 695 - 701.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
K. J. van Doorn, D. Pierard, D. Verbeelen, B. Basnyat, A. K.M. Zaidi, R. Hasan, Z. A. Bhutta, C. M. Parry, T. T. Hien, N. J. White, et al.
Typhoid Fever
N. Engl. J. Med., March 20, 2003; 348(12): 1182 - 1184.
[Full Text] [PDF]


Home page
CirculationHome page
R. Chenevard, D. Hurlimann, M. Bechir, F. Enseleit, L. Spieker, M. Hermann, W. Riesen, S. Gay, R. E. Gay, M. Neidhart, et al.
Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease
Circulation, January 28, 2003; 107(3): 405 - 409.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Chia, C. A. Ludlam, K. A. A. Fox, and D. E. Newby
Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men
J. Am. Coll. Cardiol., January 15, 2003; 41(2): 333 - 339.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T Lenderink, E Boersma, C Heeschen, A Vahanian, M.-J de Boer, V Umans, M.J.B.M van den Brand, C.W Hamm, M.L Simoons, and for the CAPTURE investigators
Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA
Eur. Heart J., January 1, 2003; 24(1): 77 - 85.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Sternik, S. Samee, H. V. Schaff, K. J. Zehr, L. O. Lerman, D. R. Holmes, J. Herrmann, and A. Lerman
C-Reactive Protein Relaxes Human Vessels In Vitro
Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1865 - 1868.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Bergholm, M. Leirisalo-Repo, S. Vehkavaara, S. Makimattila, M.-R. Taskinen, and H. Yki-Jarvinen
Impaired Responsiveness to NO in Newly Diagnosed Patients With Rheumatoid Arthritis
Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1637 - 1641.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Pleiner, F. Mittermayer, G. Schaller, R. J. MacAllister, and M. Wolzt
High Doses of Vitamin C Reverse Escherichia coli Endotoxin-Induced Hyporeactivity to Acetylcholine in the Human Forearm
Circulation, September 17, 2002; 106(12): 1460 - 1464.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. K. Koh, J. Y. Ahn, D. K. Jin, B.-K. Yoon, H. S. Kim, D. S. Kim, M.-S. Shin, J. W. Son, I. S. Choi, and E. K. Shin
Effects of Continuous Combined Hormone Replacement Therapy on Inflammation in Hypertensive and/or Overweight Postmenopausal Women
Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1459 - 1464.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. K. Koh
Effects of estrogen on the vascular wall: vasomotor function and inflammation
Cardiovasc Res, September 1, 2002; 55(4): 714 - 726.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. B. Vallbracht, P. L. Schwimmbeck, B. Seeberg, U. Kuhl, and H.-P. Schultheiss
Endothelial dysfunction of peripheral arteries in patients with immunohistologically confirmed myocardial inflammation correlates with endothelial expression of human leukocyte antigens and adhesion molecules in myocardial biopsies
J. Am. Coll. Cardiol., August 7, 2002; 40(3): 515 - 520.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. A. Vita and J. Loscalzo
Shouldering the Risk Factor Burden: Infection, Atherosclerosis, and the Vascular Endothelium
Circulation, July 9, 2002; 106(2): 164 - 166.
[Full Text] [PDF]


Home page
CirculationHome page
R. K. Kharbanda, B. Walton, M. Allen, N. Klein, A. D. Hingorani, R. J. MacAllister, and P. Vallance
Prevention of Inflammation-Induced Endothelial Dysfunction: A Novel Vasculo-Protective Action of Aspirin
Circulation, June 4, 2002; 105(22): 2600 - 2604.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A.D. Pradhan and P.M. Ridker
Do atherosclerosis and type 2 diabetes share a common inflammatory basis?
Eur. Heart J., June 1, 2002; 23(11): 831 - 834.
[Full Text] [PDF]


Home page
CirculationHome page
N. Parchure, E. G. Zouridakis, and J. C. Kaski
Effect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and Evidence of Chlamydia pneumoniae Infection
Circulation, March 19, 2002; 105(11): 1298 - 1303.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
C. Stollberger and J. Finsterer
Role of Infectious and Immune Factors in Coronary and Cerebrovascular Arteriosclerosis
Clin. Vaccine Immunol., March 1, 2002; 9(2): 207 - 215.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Pleiner, E. Heere-Ress, H. Langenberger, A. E. Sieder, M. Bayerle-Eder, F. Mittermayer, G. Fuchsjager-Mayrl, J. Bohm, B. Jansen, and M. Wolzt
Adrenoceptor Hyporeactivity Is Responsible for Escherichia coli Endotoxin-Induced Acute Vascular Dysfunction in Humans
Arterioscler Thromb Vasc Biol, January 1, 2002; 22(1): 95 - 100.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Heitzer, T. Schlinzig, K. Krohn, T. Meinertz, and T. Munzel
Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease
Circulation, November 27, 2001; 104(22): 2673 - 2678.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
G. J. Blake and P. M. Ridker
Novel Clinical Markers of Vascular Wall Inflammation
Circ. Res., October 26, 2001; 89(9): 763 - 771.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
P. Stenvinkel
Endothelial dysfunction and inflammation--is there a link?
Nephrol. Dial. Transplant., October 1, 2001; 16(10): 1968 - 1971.
[Full Text] [PDF]


Home page
CirculationHome page
F. Tomai, F. Crea, A. Gaspardone, F. Versaci, A. S. Ghini, L. Chiariello, and P. A. Gioffre
Unstable Angina and Elevated C-Reactive Protein Levels Predict Enhanced Vasoreactivity of the Culprit Lesion
Circulation, September 25, 2001; 104(13): 1471 - 1476.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. Y. M. WANG, J. WOO, M. WANG, M. M. M. SEA, R. IP, P. K. T. LI, S. F. LUI, and J. E. SANDERSON
Association of Inflammation and Malnutrition with Cardiac Valve Calcification in Continuous Ambulatory Peritoneal Dialysis Patients
J. Am. Soc. Nephrol., September 1, 2001; 12(9): 1927 - 1936.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
JAMA, July 18, 2001; 286(3): 327 - 334.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. P. Tiefenbacher
Tetrahydrobiopterin: a critical cofactor for eNOS and a strategy in the treatment of endothelial dysfunction?
Am J Physiol Heart Circ Physiol, June 1, 2001; 280(6): H2484 - H2488.
[Full Text] [PDF]


Home page
JAMAHome page
J. C. Chambers, L. Fusi, I. S. Malik, D. O. Haskard, M. De Swiet, and J. S. Kooner
Association of Maternal Endothelial Dysfunction With Preeclampsia
JAMA, March 28, 2001; 285(12): 1607 - 1612.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. Ghiadoni, A. E. Donald, M. Cropley, M. J. Mullen, G. Oakley, M. Taylor, G. O'Connor, J. Betteridge, N. Klein, A. Steptoe, et al.
Mental Stress Induces Transient Endothelial Dysfunction in Humans
Circulation, November 14, 2000; 102(20): 2473 - 2478.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. H. McDermott, J. P.J. Halcox, W. H. Schenke, M. A. Waclawiw, M. N. Merrell, N. Epstein, A. A. Quyyumi, and P. M. Murphy
Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis
Circ. Res., August 31, 2001; 89(5): 401 - 407.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hingorani, A. D.
Right arrow Articles by Vallance, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hingorani, A. D.
Right arrow Articles by Vallance, P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITROGLYCERIN
*VERAPAMIL HYDROCHLORIDE
Related Collections
Right arrow Acute coronary syndromes
Right arrow Endothelium/vascular type/nitric oxide